Data from ongoing clinical trials will help to address the questions on whether we can apply PARPi beyond BRCA1/2-mutated prostate cancer; whether combining PARPi with either AR signaling inhibitors or checkpoint inhibitors will work better in HRR-deficient mCRPC than HRR-intact mCRPC. The gene discussed is AR; the disease is prostate carcinoma.